Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab
Blinatumomab has demonstrated significant efficacy in adult and pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-cell ALL) and patients with measurable residual disease (MRD). This review aimed to compare median relapse-free survival (RFS) and median overall sur...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-10-01
|
| Series: | Therapeutic Advances in Hematology |
| Online Access: | https://doi.org/10.1177/20406207231201454 |
| _version_ | 1827796719980511232 |
|---|---|
| author | Hagop M. Kantarjian Aaron C. Logan Faraz Zaman Nicola Gökbuget Ralf C. Bargou Yi Zeng Gerhard Zugmaier Franco Locatelli |
| author_facet | Hagop M. Kantarjian Aaron C. Logan Faraz Zaman Nicola Gökbuget Ralf C. Bargou Yi Zeng Gerhard Zugmaier Franco Locatelli |
| author_sort | Hagop M. Kantarjian |
| collection | DOAJ |
| description | Blinatumomab has demonstrated significant efficacy in adult and pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-cell ALL) and patients with measurable residual disease (MRD). This review aimed to compare median relapse-free survival (RFS) and median overall survival (OS) in adult and pediatric patients with R/R or MRD-positive B-cell ALL from pivotal studies [MT-103-211 and TOWER for adults with Philadelphia chromosome (Ph)-negative R/R B-cell ALL, ALCANTARA for adults with Ph-positive R/R B-cell ALL, MT-103-203 for adults with MRD-positive B-cell ALL, and MT-103-205 for pediatric patients with R/R B-cell ALL], with the median RFS and OS from retrospective analyses, country or ethnicity-specific studies, and studies based on real-world evidence (RWE) identified from a literature search. Adults with Ph-negative R/R B-cell ALL who received blinatumomab as first salvage demonstrated a numerically longer median OS compared with that in patients from pivotal studies (MT-103-211 and TOWER) without additional safety concerns. In pediatric patients with R/R B-cell ALL treated with blinatumomab, the median RFS and OS from retrospective analyses and country/ethnicity-specific studies were comparable with the median RFS and OS from the pivotal study MT-103-205. The median RFS and OS from RWE studies in adults with R/R B-cell ALL were numerically longer than the median RFS and OS from pivotal studies (MT-103-211, TOWER, and ALCANTARA); however, this trend was not observed in pediatric patients with R/R B-cell ALL. In conclusion, this analysis identified first salvage adults with Ph-negative R/R B-cell ALL as particularly well-suited for treatment with blinatumomab since survival outcomes from retrospective analyses reported in this patient subgroup were numerically better compared with those from pivotal studies without additional safety signals. |
| first_indexed | 2024-03-11T19:11:04Z |
| format | Article |
| id | doaj.art-5fc82631f9ff44c4bd0d8b792db0795d |
| institution | Directory Open Access Journal |
| issn | 2040-6215 |
| language | English |
| last_indexed | 2024-03-11T19:11:04Z |
| publishDate | 2023-10-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Hematology |
| spelling | doaj.art-5fc82631f9ff44c4bd0d8b792db0795d2023-10-09T17:03:40ZengSAGE PublishingTherapeutic Advances in Hematology2040-62152023-10-011410.1177/20406207231201454Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomabHagop M. KantarjianAaron C. LoganFaraz ZamanNicola GökbugetRalf C. BargouYi ZengGerhard ZugmaierFranco LocatelliBlinatumomab has demonstrated significant efficacy in adult and pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-cell ALL) and patients with measurable residual disease (MRD). This review aimed to compare median relapse-free survival (RFS) and median overall survival (OS) in adult and pediatric patients with R/R or MRD-positive B-cell ALL from pivotal studies [MT-103-211 and TOWER for adults with Philadelphia chromosome (Ph)-negative R/R B-cell ALL, ALCANTARA for adults with Ph-positive R/R B-cell ALL, MT-103-203 for adults with MRD-positive B-cell ALL, and MT-103-205 for pediatric patients with R/R B-cell ALL], with the median RFS and OS from retrospective analyses, country or ethnicity-specific studies, and studies based on real-world evidence (RWE) identified from a literature search. Adults with Ph-negative R/R B-cell ALL who received blinatumomab as first salvage demonstrated a numerically longer median OS compared with that in patients from pivotal studies (MT-103-211 and TOWER) without additional safety concerns. In pediatric patients with R/R B-cell ALL treated with blinatumomab, the median RFS and OS from retrospective analyses and country/ethnicity-specific studies were comparable with the median RFS and OS from the pivotal study MT-103-205. The median RFS and OS from RWE studies in adults with R/R B-cell ALL were numerically longer than the median RFS and OS from pivotal studies (MT-103-211, TOWER, and ALCANTARA); however, this trend was not observed in pediatric patients with R/R B-cell ALL. In conclusion, this analysis identified first salvage adults with Ph-negative R/R B-cell ALL as particularly well-suited for treatment with blinatumomab since survival outcomes from retrospective analyses reported in this patient subgroup were numerically better compared with those from pivotal studies without additional safety signals.https://doi.org/10.1177/20406207231201454 |
| spellingShingle | Hagop M. Kantarjian Aaron C. Logan Faraz Zaman Nicola Gökbuget Ralf C. Bargou Yi Zeng Gerhard Zugmaier Franco Locatelli Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab Therapeutic Advances in Hematology |
| title | Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab |
| title_full | Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab |
| title_fullStr | Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab |
| title_full_unstemmed | Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab |
| title_short | Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab |
| title_sort | survival outcomes in patients with relapsed refractory or mrd positive b cell acute lymphoblastic leukemia treated with blinatumomab |
| url | https://doi.org/10.1177/20406207231201454 |
| work_keys_str_mv | AT hagopmkantarjian survivaloutcomesinpatientswithrelapsedrefractoryormrdpositivebcellacutelymphoblasticleukemiatreatedwithblinatumomab AT aaronclogan survivaloutcomesinpatientswithrelapsedrefractoryormrdpositivebcellacutelymphoblasticleukemiatreatedwithblinatumomab AT farazzaman survivaloutcomesinpatientswithrelapsedrefractoryormrdpositivebcellacutelymphoblasticleukemiatreatedwithblinatumomab AT nicolagokbuget survivaloutcomesinpatientswithrelapsedrefractoryormrdpositivebcellacutelymphoblasticleukemiatreatedwithblinatumomab AT ralfcbargou survivaloutcomesinpatientswithrelapsedrefractoryormrdpositivebcellacutelymphoblasticleukemiatreatedwithblinatumomab AT yizeng survivaloutcomesinpatientswithrelapsedrefractoryormrdpositivebcellacutelymphoblasticleukemiatreatedwithblinatumomab AT gerhardzugmaier survivaloutcomesinpatientswithrelapsedrefractoryormrdpositivebcellacutelymphoblasticleukemiatreatedwithblinatumomab AT francolocatelli survivaloutcomesinpatientswithrelapsedrefractoryormrdpositivebcellacutelymphoblasticleukemiatreatedwithblinatumomab |